On Oct 25, major Wall Street analysts update their ratings for $Marinus Pharmaceuticals (MRNS.US)$, with price targets ranging from $3 to $3.
TD Cowen analyst Joseph Thome maintains with a hold rating.
Oppenheimer analyst Jay Olson maintains with a buy rating.
Truist Financial analyst Joon Lee maintains with a hold rating.
EF Hutton analyst Jason Kolbert initiates coverage with a buy rating, and sets the target price at $3.
JMP Securities analyst Jason Butler downgrades to a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Marinus Pharmaceuticals (MRNS.US)$'s main analysts recently are as follows:
Marinus Pharmaceuticals' oral ganaxolone in a Phase III study for tuberous sclerosis complex rare epilepsy did not achieve a significant difference in placebo-adjusted percent change. Despite this, there may still be potential for revenue generation in CDD, and if the stock's value remains low following an 80% decrease, an arbitrage opportunity could present itself.
Marinus Pharmaceuticals' recent Phase III trial of ganaxolone in tuberous sclerosis complex did not achieve the primary endpoint. This has led to concerns regarding the company's limited financial runway and the uncertain future direction following these results.
Marinus Pharmaceuticals' Phase III study of oral ganaxolone in tuberous sclerosis complex rare-epilepsy did not achieve the primary endpoint of reducing seizures. Analysts believe this outcome has led to a lack of immediate catalysts anticipated before 2025.
Marinus Pharmaceuticals' announcement regarding the Phase 3 study of ganaxolone in TSC not meeting its primary endpoint has prompted the company to explore strategic alternatives. This development eliminates the possibility of a Ztalmy label expansion which was anticipated to substantially enhance revenues beyond its use in CDD.
Here are the latest investment ratings and price targets for $Marinus Pharmaceuticals (MRNS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月25日，多家華爾街大行更新了$Marinus Pharmaceuticals (MRNS.US)$的評級，目標價介於3美元至3美元。
TD Cowen分析師Joseph Thome維持持有評級。
奧本海默控股分析師Jay Olson維持買入評級。
儲億銀行分析師Joon Lee維持持有評級。
EF赫頓分析師Jason Kolbert首次給予買入評級，目標價3美元。
JMP Securities分析師Jason Butler下調至持有評級。
此外，綜合報道，$Marinus Pharmaceuticals (MRNS.US)$近期主要分析師觀點如下：
marinus pharmaceuticals口服甘澤酮在針對結節性硬化症罕見癲癇的三期研究中，未能實現安慰劑調整的百分比變化的顯著差異。儘管如此，在CDD領域仍有營業收入潛力，如果股價在80%下跌後仍保持較低水平，可能會出現套戥機會。
marinus pharmaceuticals最近在結節性硬化症的甘澤酮三期試驗未達到主要終點。這引發了對公司有限的財務資金週轉和在這些結果之後未來方向的擔憂。
marinus pharmaceuticals口服甘澤酮在針對結節性硬化症罕見癲癇的三期研究中未達到減少癲癇發作的主要終點。分析師們認爲這一結果導致了2025年之前預期的立即催化劑的缺乏。
marinus pharmaceuticals關於甘澤酮在TSC的三期研究未達到主要終點的公告促使公司探索戰略替代方案。這一進展消除了Ztalmy標籤擴展的可能性，這被預期能夠顯著增加除了在CDD中使用以外的營業收入。
以下爲今日5位分析師對$Marinus Pharmaceuticals (MRNS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
